189 related articles for article (PubMed ID: 18632643)
1. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells.
Regala RP; Thompson EA; Fields AP
Cancer Res; 2008 Jul; 68(14):5888-95. PubMed ID: 18632643
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.
Fields AP; Regala RP
Pharmacol Res; 2007 Jun; 55(6):487-97. PubMed ID: 17570678
[TBL] [Abstract][Full Text] [Related]
3. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
4. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.
Erdogan E; Lamark T; Stallings-Mann M; Lee Jamieson ; Pellecchia M; Thompson EA; Johansen T; Fields AP
J Biol Chem; 2006 Sep; 281(38):28450-9. PubMed ID: 16861740
[TBL] [Abstract][Full Text] [Related]
5. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.
Regala RP; Weems C; Jamieson L; Khoor A; Edell ES; Lohse CM; Fields AP
Cancer Res; 2005 Oct; 65(19):8905-11. PubMed ID: 16204062
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma.
Kikuchi K; Soundararajan A; Zarzabal LA; Weems CR; Nelon LD; Hampton ST; Michalek JE; Rubin BP; Fields AP; Keller C
Oncogene; 2013 Jan; 32(3):286-95. PubMed ID: 22349825
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.
Mansfield AS; Fields AP; Jatoi A; Qi Y; Adjei AA; Erlichman C; Molina JR
Anticancer Drugs; 2013 Nov; 24(10):1079-83. PubMed ID: 23962904
[TBL] [Abstract][Full Text] [Related]
8. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
[TBL] [Abstract][Full Text] [Related]
9. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.
Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP
Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040
[TBL] [Abstract][Full Text] [Related]
10. A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma.
Pillai P; Desai S; Patel R; Sajan M; Farese R; Ostrov D; Acevedo-Duncan M
Int J Biochem Cell Biol; 2011 May; 43(5):784-94. PubMed ID: 21315177
[TBL] [Abstract][Full Text] [Related]
11. Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis.
Ratnayake WS; Apostolatos AH; Ostrov DA; Acevedo-Duncan M
Int J Oncol; 2017 Nov; 51(5):1370-1382. PubMed ID: 29048609
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation.
Kim CY; Giaccia AJ; Strulovici B; Brown JM
Br J Cancer; 1992 Nov; 66(5):844-9. PubMed ID: 1329908
[TBL] [Abstract][Full Text] [Related]
13. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota.
Guo W; Wu S; Liu J; Fang B
Cancer Res; 2008 Sep; 68(18):7403-8. PubMed ID: 18794128
[TBL] [Abstract][Full Text] [Related]
14. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
15. Regulation of glioblastoma cell invasion by PKC iota and RhoB.
Baldwin RM; Parolin DA; Lorimer IA
Oncogene; 2008 Jun; 27(25):3587-95. PubMed ID: 18212741
[TBL] [Abstract][Full Text] [Related]
16. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
Fields AP; Frederick LA; Regala RP
Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
18. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance.
Clark AS; West KA; Blumberg PM; Dennis PA
Cancer Res; 2003 Feb; 63(4):780-6. PubMed ID: 12591726
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway.
Ding L; Wang H; Lang W; Xiao L
J Biol Chem; 2002 Sep; 277(38):35305-13. PubMed ID: 12121973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
